| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 19, 2004
Accepted on July 30, 2004
(1,3)Fucosyltransferases FucT-IV and FucT-VII Control Susceptibility to Atherosclerosis in Apolipoprotein E-/- Mice
From the Department of Pathology and The Howard Hughes Medical Institute (J.W.H., J.B.L.), University of Michigan, Ann Arbor, Mich; and the Department of Medicine (A.D.), Gill Heart Institute, University of Kentucky, Lexington.
* To whom correspondence should be addressed. E-mail: homeiste{at}umich.edu.
Objective--These studies examine the contributions of
(1,3)fucosyltransferases (FucT) IV and VII to the generation of selectin counter-receptors necessary for selectin-dependent atherogenesis. They also determine the functional contribution of FucT-IV and FucT-VII to shear-dependent tethering of monocytes to P-selectin, a process believed to be required for atherogenesis.
Methods and Results--Atherosclerotic lesion size and histology were determined in apolipoprotein E-/- mice sufficient or deficient in FucT-IV or FucT-VII. Lesion size was subtly reduced in FucT-IV-deficient mice and significantly reduced in FucT-VII-deficient mice. FucT deficiency did not alter lesion histology, plasma total cholesterol, or the lipoprotein distribution profile. Atheroprotection in FucT-IV or FucT-VII deficiency aligned with subtle and profound reductions, respectively, of P-selectin counter-receptor activity on peripheral blood monocytes as determined by tethering to P-selectin-IgG in vitro under shear flow.
Conclusions--FucT-VII-mediated
(1,3)fucosylation of selectin ligands is a necessary concomitant to atherogenesis in apoE-/- mice and is required for P-selectin-dependent peripheral blood monocyte adhesion under shear stress. FucT-IV deficiency yields subtle deficits in monocyte P-selectin counter-receptor activity and is associated with a subtle decrement in atherosclerosis. These studies identify an important role for FucT-VII in atherogenesis, and a subsidiary role for FucT-IV, and implicate leukocyte selectin counter-receptors in the pathogenesis of atherosclerosis.
This article has been cited by other articles:
![]() |
J. M. Gitlin, J. W. Homeister, J. Bulgrien, J. Counselman, L. K. Curtiss, J. B. Lowe, and W. A. Boisvert Disruption of Tissue-Specific Fucosyltransferase VII, an Enzyme Necessary for Selectin Ligand Synthesis, Suppresses Atherosclerosis in Mice Am. J. Pathol., January 1, 2009; 174(1): 343 - 350. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Itoh, S. Sakaue, H. Nakagawa, M. Kurogochi, H. Ohira, K. Deguchi, S.-I. Nishimura, and M. Nishimura Analysis of N-glycan in serum glycoproteins from db/db mice and humans with type 2 diabetes Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E1069 - E1077. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Martinez, M. Joffraud, S. Giraud, B. Baisse, M. P. Bernimoulin, M. Schapira, and O. Spertini Regulation of PSGL-1 Interactions with L-selectin, P-selectin, and E-selectin: ROLE OF HUMAN FUCOSYLTRANSFERASE-IV AND -VII J. Biol. Chem., February 18, 2005; 280(7): 5378 - 5390. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |